.jpg)
Delray Medical Center now offers the WATCHMAN FLX™ for patients who have a high risk of stroke with non-valvular atrial fibrillation (NVAF) who need an alternative to oral anticoagulation therapy by permanently closing off the left atrial appendage-the area of the heart where stroke-causing blood clots commonly form in NAVF.
“People with atrial fibrillation are at an increased risk of stroke if they are not on blood thinners, which can also increase the risk of bleeding. This can often result in higher mortality and disability rates because of an injury to the brain or other affected areas,” said Dr. Martin Kloosterman, electrophysiologist on staff at Delray Medical Center. “We are pleased to have available a new generation of the Watchman FLX device, which expands the number of patients who can benefit from this life saving technology.”
This technology features a new, fully rounded design offering physicians the ability to safely enter, and maneuver within the left atrial appendage. It is the first LAAC device that can be fully recaptured, repositioned and redeployed for precise placement, and the new frame design allows for optimal device engagement with the tissue for long-term stability and a faster, more complete seal.
